Bespoke Gene Therapy Consortium Coordination Center (BGTC CC) Electronic Data Capture (EDC) Platform Support
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIDA
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HHSN316201500008W75N95025F00001 in this department, oldest first.
- Nov 21, 2024Award NoticeIQVIA GOVERNMENT SOLUTIONS INC · $5.6MOpen
- Nov 21, 2024 · this noticeJustification (Sole Source)
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- The agency intends to buy without full competition. Read the justification for the reason and the named source.
What the notice says
The objective of this acquisition is to obtain cloud platform services to support data collection, dissemination, analysis, integration, reporting, and management of the BGTC. The BGTC is part of the Accelerating Medicines Partnership (AMP) program, a public�private partnership among NIH, the U.S. Food and Drug Administration (FDA), multiple pharmaceutical and life sciences companies, and nonprofit and other organizations. The AMP program, which is managed by the Foundation for the NIH (FNIH), aims to improve current models for developing diagnostics and therapies. NCATS is the lead NIH IC for… (show all)
BGTC, one of several NCATS-led programs aligned with the NCATS� mission to re-engineer the translational research process so new treatments and cures for diseases can be delivered to patients faster. The BGTC is establishing platforms and standards to speed the development and delivery of customized or �bespoke� gene therapies (GT) that could treat millions of people affected by rare diseases, including diseases too rare to be of commercial interest.
Who won similar work
257 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
Single-winner award sizes (190): middle half $115K to $20.0M, median $1.3M; range $12K to $89.0B.
| Winner | Awards | Value | Last |
|---|---|---|---|
| BECTON, DICKINSON AND COMPANY · $BDX · $19.4B | 4 | $1.9M | Jan 26, 2026 |
| DUKE UNIVERSITY Durham NC 27705 USA | 3 | $36.3M + 1 shared | Dec 21, 2025 |
| Axle Informatics Rockville MD 20852 USA | 3 | $24.5M | May 22, 2025 |
| Axle Informatics, LLC | 3 | $15.4M | Dec 15, 2025 |
| BRUKER BIOSPIN CORP · $BRKR · $3.0B | 3 | $1.7M | Jul 30, 2026 |
| AGILENT TECHNOLOGIES INC · $A · $6.8B | 3 | $445K | Jul 24, 2025 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 3 | $318K | Jan 9, 2026 |
| Multiple_Awards Bethesda MD USA | 2 | $1.1B | Dec 17, 2024 |
| FISHER BIOSERVICES INC | 2 | $148.0M | Oct 7, 2026 |
| Coriell Institute for Medical Research, Inc. | 2 | $58.8M | Aug 1, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $BDX reported $19.4B revenue in FY2025. The median single-winner award in these 190 past awards, $1.3M, is under 0.1% of that. 10-K
- $BRKR reported $3.0B revenue in FY2025. The median single-winner award in these 190 past awards, $1.3M, is under 0.1% of that. 10-K
- $A reported $6.8B revenue in FY2025. The median single-winner award in these 190 past awards, $1.3M, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 9, 2026Revvity Health Sciences, Inc.$21KAutomated Cell Counter and Analyzer
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Sep 30, 2026Washington Metropolitan Area Transit Authority Washington DC 20024 USA$23.8MNIH TRANShare Program -WMATA SmartBenefits� Program Transit Benefit Services
- Sep 29, 2026THE BROAD INSTITUTE, INC$215KWhole genome sequencing for investigation of age-related chronic disease in HANDLS participants
- Sep 28, 2026Versiti Blood Health, Inc.$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation Study
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 3 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.